Sunday, April 27, 2025

AbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies

Related stories

How Enterprise General Intelligence Enhances Decision-Making in Large Organizations

In today's world, data drives strategy. Companies face pressure...

Atomicwork unveils Universal Agent with Multimodal AI

This first-of-its-kind Universal Agent eliminates manual work with Voice...

Ascendion Acquires UXReactor to Boost AI-Driven UX

Strategic acquisition of UXReactor enhances Ascendion's AI-driven experience design,...
spot_imgspot_img

AbbVie Inc. and BigHat Biosciences, announced a research collaboration to discover and develop next-generation therapeutic antibodies in oncology and neuroscience. Working closely with AbbVie, BigHat will utilize its Milliner platform, a suite of machine learning technologies integrated with a high-speed wet lab, to guide the design and selection for high quality antibodies for multiple therapeutic targets.

“This collaboration further demonstrates our commitment to integrate AI/ML-based approaches in drug discovery and development, as we strive to accelerate our oncology and neuroscience pipeline, and deliver better medicines faster,” said Jonathon Sedgwick, Ph.D., vice president and global head of discovery research at AbbVie. “We look forward to working with BigHat’s team to design novel antibody-based therapies that may help address persistent unmet needs faced by patients.”

“We are thrilled to collaborate with AbbVie, a global leader in driving innovation in drug development, and look forward to employing our Milliner™ platform to help design next-generation therapeutic antibodies,” said Mark DePristo, CEO, BigHat. “Milliner™ allows rapid optimization of multiple key parameters including functionality and developability, to help deliver complex antibodies with improved characteristics faster.”

Also Read: WiMi Announced Big Data Intelligent Decision-making System Based on Machine Learning and Situational Awareness

Under the terms of the agreement, BigHat will receive an upfront payment of $30 million and may be eligible to receive up to approximately $325 million in aggregate research and development milestones, with potential for further commercial milestones as well as tiered royalties on net sales.

AbbVie‘s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio.

BigHat Biosciences designs safer, more effective biologic therapies for patients using machine learning and synthetic biology. BigHat integrates a wet lab for high-speed characterization with machine learning technologies to guide the search for better antibodies.

SOURCE: PRNewswire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img